Laboratorios Farmaceuticos Rovi (ES:ROVI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Laboratorios Farmacéuticos Rovi, S.A. has reported its operations on own shares for the second quarter of 2024, indicating active trading under its liquidity contract with Bestinver SV, S.A. The company concluded the quarter with a final balance of 92,369 shares and a cash account balance of nearly 6 million euros, reflecting a dynamic market performance.
For further insights into ES:ROVI stock, check out TipRanks’ Stock Analysis page.